Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:ACRV

Acrivon Therapeutics Q1 2026 Earnings Report

Acrivon Therapeutics logo
$2.08 -0.09 (-4.15%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$2.11 +0.03 (+1.39%)
As of 09:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Acrivon Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.49
Beat/Miss
N/A
One Year Ago EPS
N/A

Acrivon Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.28 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acrivon Therapeutics Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Acrivon Therapeutics Earnings Headlines

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads ...
April 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/acrivon-to-highlight-preclinical-data-with-three-posters-at-aacr-demonstrating-strong-acr-368-and-acr-2316-synergies-with-immune-checkpoint-inhibitors-and-adc-payloads-revealing-broad-clinical-1036034567
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
April 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/17/3276471/0/en/acrivon-to-highlight-preclinical-data-with-three-posters-at-aacr-demonstrating-strong-acr-368-and-acr-2316-synergies-with-immune-checkpoint-inhibitors-and-adc-payloads-revealing-br.html
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/15/3274879/0/en/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Acrivon Highlights Positive ACR-368 Data and 2025 Results
March 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/acrivon-highlights-positive-acr-368-data-and-2025-results?utm_source=marketbeat.com&utm_medium=referral
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
March 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/19/3258877/0/en/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights.html
See More Acrivon Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acrivon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acrivon Therapeutics and other key companies, straight to your email.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials. In parallel, Acrivon is advancing additional stapled-peptide programs directed at other oncogenic KRAS mutants such as G12D, with the goal of expanding its pipeline to address multiple unmet needs in solid tumor oncology.

Acrivon was established in 2021 as a spin-out from Calibr, the drug discovery division of The Scripps Research Institute, and is headquartered in Redwood City, California. The company leverages its origin in academic research to maintain close collaborations with leading cancer centers and translational science groups across North America and Europe.

Supported by a management team with extensive experience in biotechnology and pharmaceutical drug development, Acrivon is building strategic partnerships and advancing its peptide platform to potentially deliver first-in-class or best-in-class therapies for patients with RAS-mutant cancers. The company continues to focus on rigorous clinical development and regulatory engagement to bring novel peptide-based oncology treatments to market.

View Acrivon Therapeutics Profile
Earnings Tools